TrialBlood advances2024

High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.

Noa G Holtzman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.